These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28818469)

  • 21. Effectiveness and safety of influenza vaccination in children: European perspective.
    Heikkinen T; Heinonen S
    Vaccine; 2011 Oct; 29(43):7529-34. PubMed ID: 21820481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivated influenza vaccine effectiveness against influenza-like illness among young children in Japan--with special reference to minimizing outcome misclassification.
    Ochiai H; Fujieda M; Ohfuji S; Fukushima W; Kondo K; Maeda A; Nakano T; Kamiya H; Hirota Y;
    Vaccine; 2009 Nov; 27(50):7031-5. PubMed ID: 19786133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Influenza vaccination present and future].
    Eich G
    Ther Umsch; 2007 Nov; 64(11):649-54. PubMed ID: 18581910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan.
    Sugaya N; Shinjoh M; Kawakami C; Yamaguchi Y; Yoshida M; Baba H; Ishikawa M; Kono M; Sekiguchi S; Kimiya T; Mitamura K; Fujino M; Komiyama O; Yoshida N; Tsunematsu K; Narabayashi A; Nakata Y; Sato A; Taguchi N; Fujita H; Toki M; Myokai M; Ookawara I; Takahashi T
    Euro Surveill; 2016 Oct; 21(42):. PubMed ID: 27784529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.
    Tapia MD; Sow SO; Tamboura B; Tégueté I; Pasetti MF; Kodio M; Onwuchekwa U; Tennant SM; Blackwelder WC; Coulibaly F; Traoré A; Keita AM; Haidara FC; Diallo F; Doumbia M; Sanogo D; DeMatt E; Schluterman NH; Buchwald A; Kotloff KL; Chen WH; Orenstein EW; Orenstein LAV; Villanueva J; Bresee J; Treanor J; Levine MM
    Lancet Infect Dis; 2016 Sep; 16(9):1026-1035. PubMed ID: 27261067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
    Greenberg DP; Robertson CA; Landolfi VA; Bhaumik A; Senders SD; Decker MD
    Pediatr Infect Dis J; 2014 Jun; 33(6):630-6. PubMed ID: 24445833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.
    Oh CE; Lee J; Kang JH; Hong YJ; Kim YK; Cheong HJ; Ahn YJ; Kim SH; Lee HJ
    Vaccine; 2010 Aug; 28(36):5857-63. PubMed ID: 20600483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy.
    Moro PL; Tepper NK; Grohskopf LA; Vellozzi C; Broder K
    Expert Rev Vaccines; 2012 Aug; 11(8):911-21. PubMed ID: 23002972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of influenza vaccines in pregnant women.
    Munoz FM
    Am J Obstet Gynecol; 2012 Sep; 207(3 Suppl):S33-7. PubMed ID: 22920057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
    J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influenza vaccine for children.
    Neuzil KM
    Clin Infect Dis; 2004 Mar; 38(5):689-91. PubMed ID: 14986253
    [No Abstract]   [Full Text] [Related]  

  • 32. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study.
    Heinonen S; Silvennoinen H; Lehtinen P; Vainionpää R; Ziegler T; Heikkinen T
    Lancet Infect Dis; 2011 Jan; 11(1):23-9. PubMed ID: 21106443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review.
    Lindsey BB; Armitage EP; Kampmann B; de Silva TI
    Lancet Infect Dis; 2019 Apr; 19(4):e110-e119. PubMed ID: 30553695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.
    Morelon E; Pouteil Noble C; Daoud S; Cahen R; Goujon-Henry C; Weber F; Laurent PE; Kaiserlian D; Nicolas JF
    Vaccine; 2010 Oct; 28(42):6885-90. PubMed ID: 20709000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization.
    Avtushenko SS; Sorokin EM; Zoschenkova NY; Zacharova NG; Naichin AN
    J Biotechnol; 1996 Jan; 44(1-3):21-8. PubMed ID: 8717382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent changes in influenza epidemiology and vaccination recommendations.
    Zimmerman RK
    J Fam Pract; 2005 Jan; 54(1 Suppl):S1-8. PubMed ID: 15623391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, controlled trial in children to assess the immunogenicity and safety of a thimerosal-free trivalent seasonal influenza vaccine.
    Domachowske JB; Blatter M; Chandrasekaran V; Liu A; Jain VK; Fries L
    Pediatr Infect Dis J; 2012 Jun; 31(6):605-15. PubMed ID: 22333695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
    Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B.
    Sugaya N; Nerome K; Ishida M; Matsumoto M; Mitamura K; Nirasawa M
    JAMA; 1994 Oct; 272(14):1122-6. PubMed ID: 7933325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
    Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
    Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.